PDS Biotechnology Corp. (PDSB)
Evaluation: Based on all recent filings, financial statements, and news.
See full evaluationAsk a question about PDS Biotechnology Corp. (PDSB)
Go deeper and ask any question about PDSB
Company Performance
Current Price
as of Sep 13, 2024$3.00
P/E Ratio
N/A
Market Cap
$110.46M
Description
PDS Biotechnology Corp. engages in the development of clinical-stage immunotherapies to treat various early-stage and late-stage cancers, including head and neck cancer, prostate cancer, breast cancer, cervical cancer, anal cancer, and other cancers. Its product, PDS0101, is an off the shelf immunotherapeutic that is administered by subcutaneous injection. The company was founded by Frank K. Bedu-Addo in 2005 and is headquartered in Princeton, NJ.
Metrics
Overview
- HQPrinceton, NJ
- SectorHealth Technology
- IndustryPharmaceuticals: Major
- TickerPDSB
- Price$3-1.64%
Trading Information
- Market Cap$110.46M
- Float95.85%
- Average Daily Volume (1m)217,786
- Average Daily Volume (3m)429,857
- EPS-$1.23
Company
- RevenueN/A
- Rev Growth (1yr)N/A
- Net Income-$8.33M
- Gross MarginN/A
- EBITDA MarginN/A
- EBITDA-$8.67M
- EV$74.16M
- EV/RevenueN/A
- P/EN/A
- P/SN/A
Documents
SEC Filings
Factset Street Account